

### Our Goals

---

**Primary:** Urgently advance better therapeutics, diagnostics, devices, wearables, and data utilization to improve the quality of life for people with epilepsy, NOW.

**Secondary:** Leverage the power of EVF donations to build an evergreen fund to support future investments in life changing epilepsy treatments.

EVF Round 1 Raise Goal: \$10,000,000

**Year 2 Funds needed to seed new investments**

### Progress to Date

---

EVF is committed to investing in devices, diagnostics, consumer products, data platforms, and drug therapies. EVF Year 1 portfolio includes 2 device, 1 diagnostic, and 1 drug company. The Epilepsy Ventures Fund has awarded investments to Miku, EpiWatch, Mensura, and Hexokine Therapeutics:



- **Miku:** smart baby monitoring company developing a general tonic-clonic seizure detection system with video and radar in collaboration with Boston Children's Hospital.



- **Epiwatch:** (<https://tic.jh.edu/work/epiwatch>) Seizure detection/alert service on the Apple Watch.
- **Hexokine Therapeutics:** Developing a drug that reversibly inhibits the energy process needed to produce seizures. The effectiveness of 2DG in stopping seizures has been demonstrated in 3 very well-established models of status epilepticus.
- **Mensura:** Developing a diagnostic system that rapidly determines clinically-relevant patient blood levels of AEDs at the point-of care.

### Our Project Pipeline

---

Our Epilepsy Pipeline Tracker closely monitors 30 start-up companies in epilepsy for funding consideration.

#### EVF Accelerator Course

Accelerator Course, with continued support from the Danny Did Foundation, will be offered virtually in Fall of 2022. Applications are being accepted through August 2022. Five companies will be selected to participate and will be eligible for funds from EVF. Donors under NDA will be offered a behind the scenes look at how the EVF evaluates these companies on Pitch Day.

#### Shark Tank 2022

The 2022 Shark Tank took place at The Pipeline Conference, June 5th- 6th 2022, in Santa Clara California. EVF received 15 applications for Shark Tank. The Investment Prize was conditionally awarded to Neurara for \$150,000 for the development of a micro-electrode capable of producing high-fidelity EEG data.

The \$25,000 Community Impact Award (does not receive EVF investment) was given to EpiPal, an epilepsy management app designed for caregivers.

### Fundraising

---

Total Raised by September 2022

Pledges to date: \$2.1M+

### Donor Opportunities

---

- Seeking visionary investors to seed and accelerate investments for Year 2 Portfolio
- Donations to the Epilepsy Foundation are tax deductible to the extent allowed by law and are restricted to the EVF portfolio as directed by the donor.
- Pledges are also accepted and will be 'called' as investments are made.
- Founding Fund Donors of \$500K or more have an opportunity to serve on the EVF Board.

### EVF Board

---

- Greg Mayes, CEO, Antios Therapeutics - Board Chairman
- John Dawson, Board of Directors Oxford Biomedica
- Frank Fischer, Board Chairman, Neuropace
- Robert Smith, Private Investor, Retired Fund Manager
- Wasim Malik, Director Biomarker Research, Harvard; Managing Partner Iaso Ventures
- Laura Thrall, CEO Epilepsy Foundation